Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price loss of -93.74% this year. Over the last six months, there has been a stronger performance of -95.14%. The price of RSLS leaped by -33.52% during the last 30 days period. For the last 5-days stocks have improved 46.33%.
ReShape Lifesciences Inc had a pretty Dodgy run when it comes to the market performance.
52-week price history of RSLS Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. ReShape Lifesciences Inc’s current trading price is -98.32% away from its 52-week high, while its distance from the 52-week low is 73.20%. The stock’s price range over this timeframe has been between $4.03 and $414.99. The shares of the Healthcare sector company recorded a trading volume of approximately 24.27 million for the day, which was comparatively higher than the average daily volume of 0.68 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
ReShape Lifesciences Inc (RSLS) has experienced a quarterly decline of -72.36% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.15M and boasts a workforce of 18 employees.
How Moving Averages and Trading Volume Data Work Together
RSLS’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for RSLS stands at 0.11. Similarly, the long-term debt-to-equity ratio is also 0.01.
